| Products/Services Used | Details | Operation |
|---|---|---|
| Peptide Synthesis | The ZIKV E sequences were preceded by a portion of the sequence corresponding to the last 32 aa from the Zika virus capsid, as signal peptide. For the production of VLP, we used a minimal cDNA sequence encoding a Gag polyprotein of murine leukemia virus (MLV) (Gag without its C-terminal Pol sequence) or Gag-NS1 or Gag-TR.NS1, were Gag was fused with full length NS1 or truncated NS1 consisting of the β-ladder domain of NS1 (aa 180 to 353). The design of the plasmids is summarized in Fig1. All final sequences were synthetized and optimized for mammalian cell expression at Genscript (NJ), prior to subcloning into our in-house phCMV-expression plasmid (24). | Get A Quote |
While Zika virus (ZIKV) infection induces mild disease in the majority of cases, it has been identified as responsible for microcephaly and severe neurological disorders in recent 2015-2016 outbreaks in South America and the Caribbean. Since then, several prophylactic vaccine strategies have been studied. Here, we describe the development of a ZIKV candidate vaccine consisting of bivalent enveloped virus-like particles (eVLPs) expressing a modified form of E and truncated NS1 (EG/NS1) proteins. In EG/NS1, the E transmembrane/cytoplasmic tail has been replaced with those domains from the VSV G protein and a β-domain of NS1 was fused in-frame to Gag from Moloney murine leukemia virus (MLV). Immunization of BALB/... More
